Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ahmad Awada

Showing results (121-130 of 311) with videos related to

Pageof 32
Sort By:
Dermatology (Basel, Switzerland)|April 4, 2003
Management of cutaneous locoregional recurrences of melanoma: a new therapeutic perspective with imiquimodPierre Vereecken, Anne Mathieu, Marianne Laporte, et al.
Cancers|December 21, 2017
PRIMA-1 and PRIMA-1<sup>Met</sup> (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial TherapiesAnne Perdrix, Ahmad Najem, Sven Saussez, et al.
European Journal of Cancer (Oxford, England : 1990)|February 25, 2014
Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenibMohammad Krayem, Fabrice Journe, Murielle Wiedig, et al.
The Oncologist|July 21, 2021
Analyses of the Rationale and Implementation of Research Biopsies in Oncology Clinical Trials at a Tertiary Cancer CenterNathalie Olympios, Laetitia Collet, Marianne Paesmans, et al.
International Journal of Oncology|July 10, 2013
Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: a rationale to combine targeted drugs based on protein expression inhibition profilesPhilippe G Aftimos, Murielle Wiedig, Mireille Langouo Fontsa, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2008
The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patientsChristoph C Zielinski, Ahmad Awada, David A Cameron, et al.
F1000Research|January 10, 2015
Case Report: Mammary and rectal metastases from an ovarian cancer: report of two cases and review of literatureMounia Amzerin, Camilo Garcia, Claudia Stanciu, et al.
Anticancer Research|October 25, 2017
New Drug Combination Strategies in Melanoma: Current Status and Future DirectionsAhmad Najem, Mohammad Krayem, Anne Perdrix, et al.
Oncotarget|August 31, 2018
Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanomaMohammad Krayem, Ahmad Najem, Fabrice Journe, et al.
Breast Cancer Research and Treatment|January 10, 2015
Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studiesChris Twelves, Javier Cortes, Linda Vahdat, et al.
Pageof 32

Showing results (121-130 of 311) with videos related to

Sort By:
Pageof 32
Dermatology (Basel, Switzerland)|April 4, 2003
Management of cutaneous locoregional recurrences of melanoma: a new therapeutic perspective with imiquimodPierre Vereecken, Anne Mathieu, Marianne Laporte, et al.
Cancers|December 21, 2017
PRIMA-1 and PRIMA-1<sup>Met</sup> (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial TherapiesAnne Perdrix, Ahmad Najem, Sven Saussez, et al.
European Journal of Cancer (Oxford, England : 1990)|February 25, 2014
Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenibMohammad Krayem, Fabrice Journe, Murielle Wiedig, et al.
The Oncologist|July 21, 2021
Analyses of the Rationale and Implementation of Research Biopsies in Oncology Clinical Trials at a Tertiary Cancer CenterNathalie Olympios, Laetitia Collet, Marianne Paesmans, et al.
International Journal of Oncology|July 10, 2013
Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: a rationale to combine targeted drugs based on protein expression inhibition profilesPhilippe G Aftimos, Murielle Wiedig, Mireille Langouo Fontsa, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2008
The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patientsChristoph C Zielinski, Ahmad Awada, David A Cameron, et al.
F1000Research|January 10, 2015
Case Report: Mammary and rectal metastases from an ovarian cancer: report of two cases and review of literatureMounia Amzerin, Camilo Garcia, Claudia Stanciu, et al.
Anticancer Research|October 25, 2017
New Drug Combination Strategies in Melanoma: Current Status and Future DirectionsAhmad Najem, Mohammad Krayem, Anne Perdrix, et al.
Oncotarget|August 31, 2018
Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanomaMohammad Krayem, Ahmad Najem, Fabrice Journe, et al.
Breast Cancer Research and Treatment|January 10, 2015
Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studiesChris Twelves, Javier Cortes, Linda Vahdat, et al.
Pageof 32